Galantamine Executive Function in Parkinson's Disease
Status:
Unknown status
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine whether galantamine stabilizes or improves thinking
abilities in individuals with Parkinson's disease. Individuals included in the study have
minor complaints about thinking such as problems with concentration or memory but do not have
dementia. This medication has been shown to have a positive effect on stabilizing memory in
individuals with Alzheimer's disease. It is FDA approved for use in elderly individuals with
Alzheimer's disease. It is hypothesized that galantamine will stabilize or improve executive
and attentional functions in individuals with Parkinson's.